NIGHTSTAR THERAPEUTICS PLC ADS overview

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY RESTRICTED JURISDICTION OR ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION WALTHAM, Mass. and LONDON, June 07, 2019 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc (“ Nightstar ”) is pleased to announce that, further to the announcement on 5 June 2019 that the High Court of Justice of England and Wales had sanctioned the scheme of...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY RESTRICTED JURISDICTION OR ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION WALTHAM, Mass. and LONDON, June 05, 2019 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc (“ Nightstar ”) is pleased to announce that the High Court of Justice of England and Wales today sanctioned the scheme of arrangement under Part 26 of the Companies Act pursuant...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY RESTRICTED JURISDICTION OR ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION WALTHAM, Mass. and LONDON, May 29, 2019 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc (“ Nightstar ”) is pleased to announce an update to the expected timetable of events relating to the scheme of arrangement (the “ Scheme ”) pursuant to which Tungsten Bidco...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY RESTRICTED JURISDICTION OR ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION WALTHAM, Mass. and LONDON, May 08, 2019 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc (" Nightstar ") is pleased to announce that, at the General Meeting and the Court Meeting held earlier today in connection with the recommended acquisition of the entire issued and...

WALTHAM, Mass. and LONDON, April 26, 2019 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc ("Nightstar") (NASDAQ: NITE) today announced that both leading independent proxy advisory firms, Institutional Shareholder Services Inc. (“ISS”) and Glass Lewis & Co. (“Glass Lewis”), have recommended that Nightstar shareholders vote " FOR " the proposals relating to the proposed acquisition of Nightstar by an affiliate of Biogen Inc. (“Biogen”). To become effective, the transaction must be...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY RESTRICTED JURISDICTION OR ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION WALTHAM, Mass. and LONDON, April 16, 2019 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc (" Nightstar ") today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, with respect to the recommended...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY RESTRICTED JURISDICTION OR ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION WALTHAM, Mass. and LONDON, April 09, 2019 (GLOBE NEWSWIRE) -- On 4 March 2019, the board of Nightstar Therapeutics plc (" Nightstar ") and Biogen Switzerland Holdings GmbH (" Bidder "), a subsidiary of Biogen, Inc., announced that they had reached agreement on the...

Biogen to acquire Nightstar for US$ 25.50 per share in cash Transaction expected to be completed by mid-year 2019 WALTHAM, Mass. and LONDON, March 04, 2019 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc (" Nightstar ") (NASDAQ: NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal diseases and Biogen Inc. (" Biogen ") are pleased to announce that they have reached agreement on the terms of a recommended acquisition whereby the entire issued and to be...